{"id":"W3123908305","doi":"10.1200/jco.2021.39.3_suppl.321","title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Adverse effect; Clinical endpoint; Phases of clinical research; Cohort; Gastroenterology; Surgery; Toxicity; Cancer; Sorafenib; Clinical trial; Immunotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001689466,0.0001887561,0.001574654,0.00009014918,0.0001026822,0.00001074325,0.0001724859,0.0001668319,0.00003899859],"category_scores_gemma":[0.002306303,0.0001019981,0.0003948427,0.000241681,0.0001501559,0.00009924405,0.00004394625,0.0008014927,0.00000101689],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004091471,"about_ca_system_score_gemma":0.002877594,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001065966,"about_ca_topic_score_gemma":0.001094816,"domain_scores_codex":[0.9967676,0.0004398328,0.001779049,0.0002779254,0.0004343682,0.0003012355],"domain_scores_gemma":[0.9958922,0.002150988,0.0009060069,0.0002609487,0.0006162059,0.000173627],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02018398,0.01628193,0.8792486,0.00004222151,0.0008306919,0.00122882,0.003075056,0.0000204121,0.000008526562,0.000003272567,0.003358139,0.07571833],"study_design_scores_gemma":[0.08449443,0.0686053,0.8307397,0.0001029882,0.001092032,0.0001415942,0.001993072,0.00004971443,0.00001172811,0.00001046974,0.01265444,0.0001045252],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925572,0.001128238,0.00001156065,0.003931339,0.0004696992,0.001174771,0.00001060168,0.000006721083,0.0007098257],"genre_scores_gemma":[0.9964635,0.0002806076,0.0003874623,0.001985817,0.0006479955,0.00006174223,0.00001185423,0.00002022364,0.0001407634],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0756138,"threshold_uncertainty_score":0.5104729,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1123646056471813,"score_gpt":0.4585702125197086,"score_spread":0.3462056068725273,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}